Display options
Cite
Maleszka R, Paszkowska-Szczur K, Soczawa E, et al. Psoriasis vulgaris and familial cancer risk- a population-based study. Hered Cancer Clin Pract. 2013;11(1):6doi: 10.1186/1897-4287-11-6.
Maleszka, R., Paszkowska-Szczur, K., Soczawa, E., Boer, M., Różewicka-Czabańska, M., Wiśniewska, J., Mirecka, A., Krysztoforska, L., Adamski, Z., Lubinski, J., & Dębniak, T. (2013). Psoriasis vulgaris and familial cancer risk- a population-based study. Hereditary cancer in clinical practice, 11(1), 6. https://doi.org/10.1186/1897-4287-11-6
Maleszka, Romuald, et al. "Psoriasis vulgaris and familial cancer risk- a population-based study." Hereditary cancer in clinical practice vol. 11,1 (2013): 6. doi: https://doi.org/10.1186/1897-4287-11-6
Maleszka R, Paszkowska-Szczur K, Soczawa E, Boer M, Różewicka-Czabańska M, Wiśniewska J, Mirecka A, Krysztoforska L, Adamski Z, Lubinski J, Dębniak T. Psoriasis vulgaris and familial cancer risk- a population-based study. Hered Cancer Clin Pract. 2013 Jun 28;11(1):6. doi: 10.1186/1897-4287-11-6. PMID: 23805825; PMCID: PMC3702451.
Copy Download .nbib Format: NLM
Share it on

Hered Cancer Clin Pract. 2013 Jun 28;11(1):6. doi: 10.1186/1897-4287-11-6.

Psoriasis vulgaris and familial cancer risk- a population-based study.

Hereditary cancer in clinical practice

Romuald Maleszka, Katarzyna Paszkowska-Szczur, Ewa Soczawa, Magdalena Boer, Monika Różewicka-Czabańska, Joanna Wiśniewska, Aneta Mirecka, Lidia Krysztoforska, Zygmunt Adamski, Jan Lubinski, Tadeusz Dębniak

Affiliations

  1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Po?abska 4, 70-115 Szczecin, Poland. [email protected].

PMID: 23805825 PMCID: PMC3702451 DOI: 10.1186/1897-4287-11-6

Abstract

BACKGROUND: Follow-up studies of psoriasis patients indicate an increased risk in the occurrence of malignancies at different sites of origin. Population stratification and/or complicated interpretation of evidence on the risk of cancer (due to the small number of patients included in most series) lead to inconsistent data. Herein we investigated the risk of occurrence of malignancies at different sites of origin in a series of 517 psoriasis patients and their 1st degree relatives.

METHODS: We evaluated the tumour spectrum as well as the age of the patient at diagnosis of cancers in psoriasis families along with the observed and expected frequencies of malignancies. The distribution of 17 common mutations/polymorphisms in 10 known cancer susceptibility genes among psoriasis patients and 517 matched healthy controls were examined. No such study has been published to date.

RESULTS: The statistical comparison of the observed and expected frequencies of cancers revealed a higher than expected occurrence of Hodgkin's lymphoma among males in psoriasis families when compared to the general population (OR=1.8, 95%CI 1.6-2.1, p=0.002). There was a non-significant tendency towards a younger age of onset and overrepresentation of laryngeal cancer and leukaemia in psoriasis families. We found no major differences in the distribution of cancer susceptibility mutations among our cases and the healthy controls.

CONCLUSIONS: The results of our study suggest an increased risk of Hodgkin's lymphoma for male members of psoriasis families. Further studies are needed to confirm the findings and to evaluate whether or not the application of cancer surveillance protocols for Hodgkin's lymphoma, leukaemia and laryngeal cancer are justified in these families.

References

  1. J Eur Acad Dermatol Venereol. 2013 Jun;27(6):739-46 - PubMed
  2. N Engl J Med. 1997 Apr 10;336(15):1041-5 - PubMed
  3. J Am Acad Dermatol. 2007 Jan;56(1):169-70 - PubMed
  4. Ann Dermatol. 2009 Aug;21(3):237-42 - PubMed
  5. Nat Genet. 2010 Nov;42(11):985-90 - PubMed
  6. Carcinogenesis. 2001 Jun;22(6):899-904 - PubMed
  7. J Am Acad Dermatol. 2011 Sep;65(3):673-674 - PubMed
  8. Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 - PubMed
  9. Br J Dermatol. 1999 Jul;141(1):108-12 - PubMed
  10. Nat Genet. 2010 Nov;42(11):991-5 - PubMed
  11. Lancet. 2003 Apr 5;361(9364):1197-204 - PubMed
  12. Biochem Genet. 2003 Feb;41(1-2):27-37 - PubMed
  13. Br J Dermatol. 1999 Feb;140(2):237-42 - PubMed
  14. Int J Dermatol. 2013 Jun;52(6):705-10 - PubMed
  15. J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6 - PubMed
  16. Nat Rev Drug Discov. 2005 Jan;4(1):19-34 - PubMed
  17. Br J Dermatol. 2004 Sep;151(3):675-8 - PubMed
  18. Nat Genet. 2012 Dec;44(12):1341-8 - PubMed
  19. J Dermatol Sci. 2012 Nov;68(2):82-8 - PubMed
  20. J Natl Cancer Inst. 1998 Sep 2;90(17):1278-84 - PubMed
  21. Acta Derm Venereol. 2006;86(2):184-5 - PubMed
  22. Mol Biol Rep. 2012 Jun;39(6):6471-8 - PubMed
  23. J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):716-22 - PubMed
  24. Hum Mol Genet. 1998;7(10):1537-45 - PubMed
  25. Exp Dermatol. 2008 Sep;17(9):748-51 - PubMed
  26. J Invest Dermatol. 2001 Dec;117(6):1531-7 - PubMed
  27. J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S1-11 - PubMed
  28. Br J Cancer. 2009 May 5;100(9):1499-502 - PubMed
  29. Int J Dermatol. 2012 Dec;51(12):1454-60 - PubMed
  30. Pharmacogenet Genomics. 2005 May;15(5):349-55 - PubMed
  31. J Am Acad Dermatol. 2001 May;44(5):755-61 - PubMed
  32. J Invest Dermatol. 2000 Mar;114(3):587-90 - PubMed
  33. Rheumatol Int. 2010 Aug;30(10):1273-6 - PubMed
  34. Br J Cancer. 1983 Jun;47(6):857-9 - PubMed
  35. Eur J Dermatol. 2002 Nov-Dec;12(6):540-2 - PubMed
  36. J Invest Dermatol. 1997 Jun;108(6):897-900 - PubMed
  37. Eur J Dermatol. 2012 Mar-Apr;22(2):275-6 - PubMed
  38. Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):76-8 - PubMed
  39. J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 - PubMed
  40. Arch Dermatol. 1994 Feb;130(2):216-24 - PubMed

Publication Types